Acceleron commences ACE-536 Phase 1 clinical trial in anemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases today announced that it has initiated a Phase 1 clinical study of ACE-536. ACE-536 is a ligand trap that increases red blood cells and hemoglobin by inhibiting members of the TGF-beta superfamily involved in late stages of erythropoiesis. ACE-536 is being developed for the treatment of anemia in a global collaboration with Celgene Corporation. The Phase 1 clinical trial is a multiple-dose, dose-escalating study designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ACE-536. Acceleron will receive a $7.5 million payment from Celgene for achieving this milestone event.

"ACE-536 has the potential to make a significant impact on the treatment of anemia, specifically, in diseases such as Myelodysplastic syndromes and beta-thalassemia in which the severe anemia isn't well managed by currently available therapies. By affecting production of red blood cells via a mechanism distinct from erythropoiesis stimulating agents, ACE-536 may become an option for patients for whom current therapies are ineffective," said John Knopf, Ph.D., Chief Executive Officer of Acceleron. "Acceleron's leadership in the biology of the TGF-beta superfamily proteins and our related expertise in discovering, developing and manufacturing potent biologic modulators of these proteins has enabled incredible productivity achievements in a short period of time. ACE-536 is our fourth internally discovered, developed and manufactured drug to enter human clinical trials in the past five years."

Source: Acceleron


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Saffron: A golden remedy for modern health challenges